Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

27 results
Display

Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Outcome

Kim KI

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Letter: Association between Serum Dipeptidyl Peptidase-4 Concentration and Obesity-Related Factors in Health Screen Examinees (J Obes Metab Syndr 2017;26:188-96)

Koh G

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Novel Therapies for Type 2 Diabetes Mellitus

Ko JM

  • KMID: 1819674
  • J Korean Soc Pediatr Endocrinol.
  • 2009 Jun;14(1):11-18.
Type 2 diabetes mellitus (T2DM) is a progressive disorder caused by a combination of insulin resistance and betacell dysfunction. The role of new hormones and systems in maintaining blood glucose...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Response: Association between Serum Dipeptidyl Peptidase-4 Concentration and Obesity-Related Factors in Health Screen Examinees (J Obes Metab Syndr 2017;26:188-96)

Lee JY, Jang BK, Song MK, Kim HS, Kim MK

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Role of dipeptidyl peptidase-4 inhibitors in new-onset diabetes after transplantation

Lim SW, Jin JZ, Jin L, Jin J, Li C

Despite strict pre- and post-transplantation screening, the incidence of new-onset diabetes after transplantation (NODAT) remains as high as 60%. This complication affects the risk of cardiovascular events and patient and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Counteracting the enzymatic activity of dipeptidylpeptidase 4 for potential therapeutic advantage, with an emphasis on cord blood transplantation

Broxmeyer

Dipeptidylpeptidase (DPP) 4, also known as CD26, is an enzyme present on the surface of a number of different cell types. It is also found within cells and as a...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Increased Plasma Dipeptidyl Peptidase IV Activities in ob/ob Mice

Rhee SD, Lee YS, Lee HS, Jung WH, Cheon HG, Ahn JH, Kim SS, Paik SG, Yang SD

  • KMID: 2177801
  • J Korean Diabetes Assoc.
  • 2005 Jan;29(1):22-29.
BACKGROUND: Dipeptidyl peptidase IV (DPP IV/CD26), a multi-functional glycoprotein, cleaves and inactivates major insulinotropic hormones, such as glucagon-like protein (GLP)-1 and glucose dependent insulinotrophic polypeptide (GIP). METHODS: The plasma DPP...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Effect of Sodium-Glucose Cotransporter-2 Inhibitors versus Dipeptidyl Peptidase 4 Inhibitors on Cardiovascular Function in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease

Lee SJ, Lee KH, Oh HG, Seo HJ, Jeong SJ, Kim CH

BACKGROUND: Randomized controlled trials demonstrated lowering risks of cardiovascular events with sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with type 2 diabetes mellitus (T2DM) and high cardiovascular risk. We analyzed the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Dipeptidyl Peptidase 4 Inhibitors and the Risk of Cardiovascular Disease in Patients with Type 2 Diabetes: A Tale of Three Studies

Son JW, Kim S

Dipeptidyl peptidase 4 (DPP4) inhibitors have been touted as promising antihyperglycemic agents due to their beneficial effects on glycemia without inducing hypoglycemia or body weight gain and their good tolerability....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Factors Influencing Glycemic Control Response of Sitagliptin

Kim GW, Kim JH, Lee MY, Shin JY, Shin YG, Ha EH, Chung CH

BACKGROUND: Dipeptidyl peptidase 4 (DPP-4) inhibitors are proposed to reduce blood glucose in type 2 diabetes by prolonging the activity of circulating incretins. However, the factors that affect the efficacy...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Soluble Dipeptidyl Peptidase-4 Levels Are Associated with Decreased Renal Function in Patients with Type 2 Diabetes Mellitus

Cho EH, Kim SW

BACKGROUND: Dipeptidyl peptidase-4 (DPP-4) is strongly expressed in the kidney, and soluble levels of this protein are used as a marker in various chronic inflammatory diseases, including diabetes, coronary artery...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Predictive Clinical Parameters and Glycemic Efficacy of Vildagliptin Treatment in Korean Subjects with Type 2 Diabetes

Chang JS, Shin J, Kim HS, Kim KH, Shin JA, Yoon KH, Cha BY, Son HY, Cho JH

BACKGROUND: The aims of this study are to investigate the glycemic efficacy and predictive parameters of vildagliptin therapy in Korean subjects with type 2 diabetes. METHODS: In this retrospective study, we...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Effects of Vildagliptin or Pioglitazone on Glycemic Variability and Oxidative Stress in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A 16-Week, Randomised, Open Label, Pilot Study

Kim NH, Kim DL, Kim KJ, Kim NH, Choi KM, Baik SH, Kim SG

BACKGROUND: Glycemic variability is associated with the development of diabetic complications through the activation of oxidative stress. This study aimed to evaluate the effects of a dipeptidyl peptidase 4 inhibitor,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
High Levels of Serum DPP-4 Activity Are Associated with Low Bone Mineral Density in Obese Postmenopausal Women

Kim SW, Cho EH

BACKGROUND: Dipeptidyl peptidase 4/CD26 (DPP-4) is a widely expressed cell surface serine protease. DPP-4 inhibitors, one of common anti-diabetic agents play a protective role in bone metabolism in recent studies....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Oral Hypoglycemic Agents for Patients with Type 2 Diabetes Mellitus

Ko SH

For patients with newly diagnosed type 2 diabetes mellitus (T2DM), lifestyle modifications including medical nutrition therapy, weight control, physical activity, smoking cessation, and avoidance of alcohol abuse should be initiated....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Triple Combination Therapy Using Metformin, Thiazolidinedione, and a GLP-1 Analog or DPP-IV Inhibitor in Patients with Type 2 Diabetes Mellitus

Kim SW

Although there is no HbA1c threshold for cardiovascular risk, the American Diabetic Association-recommended goal of HbA1c < 7.0% appears to be unacceptably high. To achieve an optimal HbA1c level goal...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Changes in Adenosine Deaminase Activity in Patients with Type 2 Diabetes Mellitus and Effect of DPP-4 Inhibitor Treatment on ADA Activity

Lee JG, Kang DG, Yu JR, Kim YR, Kim JS, Koh GP, Lee DH

BACKGROUND: Dipeptidyl peptidase 4 (DPP-4, also known as CD26) binds with adenosine deaminase (ADA) to activate T lymphocytes. Here, we investigated whether ADA activity is specifically affected by treatment with...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Characteristics of Hypoglycemia Pateints Visiting the Emergency Department of a University Hospital

Choi SH, Youn DK, Choi MG, Ryu OH

BACKGROUND: Hypoglycemia is an important obstacle in the treatment of diabetes. When diabetic patients experience hypoglycemia, thorough glycemic control is more difficult. We evaluated the factors associated with risk of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Treatment of Autoimmune Diabetes by Inhibiting the Initial Event

Lee MS

Recent papers have shown that the initial event in the pathogenesis of autoimmune type 1 diabetes (T1D) comprises sensing of molecular patterns released from apoptotic beta-cells by innate immune receptors...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Sodium butyrate has context-dependent actions on dipeptidyl peptidase-4 and other metabolic parameters

Lee ES, Lee DS, Pandeya PR, Kim YC, Kang DG, Lee HS, Oh BC, Lee DH

Sodium butyrate (SB) has various metabolic actions. However, its effect on dipeptidyl peptidase 4 (DPP-4) needs to be studied further. We aimed to evaluate the metabolic actions of SB, considering...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr